• Caribou’s webcast of KOL discussion from 2024
Boyu Hu , MD, director of lymphoma and CLL in the division of hematology and hematologic malignancies,University of Utah Mehdi Hamadani , MD, professor of medicine, section chief of hematologic malignancies,Medical College of Wisconsin Rachel Haurwitz , PhD, president and chief executive officer,Caribou Biosciences
Additional participants from
Steve Kanner , PhD, chief scientific officer- Jason O’Byrne, chief financial officer
- Kike Zudaire, PhD, senior vice president, translational sciences and therapeutic discovery
Tonia Nesheiwat , PharmD, vice president of medical affairs and project leadership
•
Webcast
• Goldman Sachs 45th Annual Global Healthcare Conference,
Webcast
For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.
About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
About
Investors:
investor.relations@cariboubio.com
Media:
media@cariboubio.com
![](https://ml.globenewswire.com/media/OTZmM2M4ZjgtMmUyZi00YTQyLWFiZmEtZmQ4NDM3YjkyZTQ1LTEyMjEwNzY=/tiny/Caribou-Biosciences-Inc-.png)
2024 GlobeNewswire, Inc., source